The DCVMN Board is composed of seven elected members with skills and experiences to provide governance oversight to the DCVMN secretariat, through its Chief Executive Officer, Mr. Rajinder Kumar Suri. All Board members act on a voluntary, non-remunerated basis. The DCVMN Board meets monthly during formal governance meetings, on virtual platform, with pre-set agenda and relevant documents circulated in advance to facilitate informed decisions.
Elected for the period 2023-2025
Chair of the Board
Adriansjah is a member of the Board of Executives of Bio Farma as Senior Executive Vice President (SEVP) overseeing Research and Development activities. He has been in Bio Farma for more than 30 years with experience in bioprocessing, Quality Management and technology transfer. He has actively participated in interacting with global organizations for the company such as The Bill and Melinda Gates Foundation, PATH, CEPI and IVI on several projects. He is a pharmacist and holds a Master’s degree in Operations Management. Adriansjah was elected as president of DCVMN for the period of 2023 – 2025.
Tiago Rocca, BD
Deputy Chair of the Board
Butantan Institute, Brazil
Mr. Rocca has been working at Butantan for over 15 years and has assumed responsibilities in vaccines and biopharmaceuticals production, technology transfer, validation and QA. He is a pharmacist and post-graduated in Health Law at Public Health School USP and in Pharma Business Management at ESPM. Currently is the Secretary of Emerging Biopharmaceuticals Manufacturers Network (EBPMN).
Mr. Venkatraman Sivaramakrishnan has been working at Bharat Biotech for over 10 years.. In his current role as Vice President International Business, he oversees Global Business operations, as well as. supports the management with go to market strategies, strategic alliances with international partners and development of advocacy teams. He has 30 plus years of experience in Vaccine and Biopharmaceutical Industry... Through his affiliation with organizations such as APCRI and as an industry invitee to RIA, he has been contributing to the prevention and control of Rabies in Asia. He holds an undergraduate degree in physical sciences and; Masters in General Management and Foreign Trade
Rachel Park has been with EuBiologics from prequalification to commercialization of Euvichol-Plus, oral cholera vaccine since 2015. She’s a director in international business at EuBiologics, responsible for marketing and collaboration with international stakeholders for its pipeline development. She was a venture capitalist funding biotechnology companies prior to joining in EuBioloigcs.
Mauricio Zuma Medeiros
CEO of Bio-Manguinhos since 2017, holds a D.Phil. in Technology and Innovation Management from the University of Sussex (England) and a Master's in Science and Technology in Health from the National School of Public Health (Ensp/Fiocruz). He holds an Executive MBA from the Federal University of Rio de Janeiro (UFRJ/Coppead) and a specialization in Public Administration from the Brazilian School of Public Administration of the Getúlio Vargas Foundation (FGV). He holds a degree in Business Administration from Faculdades Integradas Bennett.
Zuma was executive director of the Foundation for Scientific and Technological Development in Health (Fiotec) from 2011 to 2017. At Bio-Manguinhos since 1994, he worked in restructuring processes and implemented management practices, such as the unit's Planning System. He managed the construction project of the Industrial Complex of Biotechnology in Health (CIBS), at the campus located in the Industrial District of Santa Cruz
Dr Sunil Gairola is the elected executive director at Serum Institute of India, (Missing bio), Responsible for vaccine quality with more than 30 years of experience in quality control, quality assurance and bioanalytic of vaccines and biosimilars. Collaborator to international initiatives of WHO, NVI, NIBSC, EDQM with interests in the harmonization of regulatory requirements of vaccines. Expert on Indian and USP Pharmacopoeia (IP) panels on vaccine and biosimilar monographs.
Andrew holds the position of General Manager at Shanghai Wotai Biotechnology, a Walvax subsidiary, and is the Director of Business Development at Walvax Biotechnology Ltd. He sustains more than 30 years of intercultural experience on molecular cancer drug, antibody therapeutics, human vaccine research, business development, global registration and sales & marketing. Through Andrew’s leadership and participation, Walvax and its subsidiary companies have received several grant and/or technical supports from DCVMN, Bill & Melinda Gates Foundation, PATH, CEPI and CHAI since 2014, in addition to the global business expansion of product registration and sales in numerous countries.
Sai D. Prasad
Advisor the Board of members and President of the General Assembly (non-voting)
Bharat Biotech International Ltd., India
Sai Prasad is the Executive Director at Bharat Biotech. He is responsible for crucial decisions in the company with respect to operations, business development and International Collaborations. He has expertise in areas not restricted to product development, contract negotiations, technology licensing, mergers & acquisitions, fund raising, overall operations, etc.
Advisor to the Board of members and Vice-President of the General Assembly (non-voting)
Biovac Institute, South Africa
Mr. Tippoo heads Science and Innovation at Biovac, in South Africa. He is a founding member and present Executive Director of the African Vaccine Manufacturing Initiative (AVMI) and currently serves as the Vice-President of DCVMN Mr. Tippoo is also advisor of the DCVMN’s board.
Sinergium Biotech, Argentina
Mr. Lobos is Engineer and MBA with 20-years’ professional experience in management, focused on new business development, engineering, start-up and operations of pharmaceutical companies. He has been working in vaccine companies for over 12 years. He holds a engineering degree from University of Buenos Aires.
New Board Members Announcement
As you would be aware the Developing Countries Vaccine Manufacturers Network (DCVMN) held elections for Board members and put forward their votes for new committee members on 19th October 2022, at the 22nd AGM in Pune, India.
We are very pleased to welcome new incoming Board members: Mr. Adriansjah Azhari, Mr. Tiago Tadeu Rocca de Moraes, Mr. Venkatraman Hariharan Sivaramakrishnan, Ms. Youngran (Rachel) Park, Dr. Mauricio Zuma Medeiros, Dr. Sunil Gairola, Dr. Andrew Zilong Wong.
All Board member roles are reviewed and, to support professional development within the Board, these roles are reallocated by vote. For your information, according to the article 3.9 and of the bylaws/internal rules, the new elected Board 2023-2025 is composed as follows:
- Mr. Adriansjah Azhari, Chair of the Board
- Mr. Tiago Tadeu Rocca de Moraes, Cochair of the Board
- Mr. Venkatraman Hariharan Sivaramakrishnan, Board Member
- Ms. Youngran (Rachel) Park, Board Member
- Dr. Mauricio Zuma Medeiros, Board Member
- Dr. Sunil Gairola, Board Member
- Dr. Andrew Zilong Wong, Board Member
We thank all the elected members for their interest and generous availability to voluntarily serve the association.
The advisors to the Board are
- Mr. Sai Prasad, President of the General Assembly and Advisor to the Board of members
- Mr. Patrick Tippoo, Vice President of the General Assembly and Advisor to the Board of members